Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction

Leukemia

Volumn 27, Issue 8, 2013, Pages 1697-1706

  Storti, P ^a   Bolzoni, M ^a   Donofrio, G ^a   Airoldi, I ^b   Guasco, D ^a   Toscani, D ^a   Martella, E ^c   Lazzaretti, M ^a   Mancini, C ^c   Agnelli, L ^d   Patrene, K ^e   Maiga S ^f   Franceschi, V ^a   Colla, S ^g   Anderson, J ^h   Neri, A ^d   Amiot, M ^f   Aversa, F ^a   David Roodman, G ^h   Giuliani, N ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITÉ DE NANTES   (France)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

angiogenesis; bone disease; hypoxia; mice; myeloma

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 7; LENALIDOMIDE; SHORT HAIRPIN RNA;

ANTIANGIOGENIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BONE DESTRUCTION; CANCER GROWTH; CANCER INHIBITION; CANCER SIZE; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MYELOMA CELL; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; GENE KNOCKDOWN TECHNIQUES; GENE SILENCING; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; OSTEOLYSIS; TUMOR BURDEN;

EID: 84881476071     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2013.24     Document Type: Article

References (50)

1. Podar K, Richardson PG, Hideshima T, Chauhan D, Anderson KC. The malignant clone and the bone-marrow environment. Best Pract Res Clin Haematol 2007; 20: 597-612. (Pubitemid 350215375)
2. Vacca A, Ribatti D, Presta M, Minischetti M, Iurlaro M, Ria R et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloprotei-nase-2 secretion parallel progression of human multiple myeloma. Blood 1999; 93: 3064-3073. (Pubitemid 29200799)
3. Vacca A, Ribatti D. Bone marrow angiogenesis in multiple myeloma. Leukemia 2006; 20: 193-199. (Pubitemid 43148652)
4. Rajkumar SV, Leong T, Roche PC. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116. (Pubitemid 30637735)
5. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001; 28: 565-569. (Pubitemid 33134415)
6. Alexandrakis MG, Passam FH, Dambaki C, Pappa CA, Stathopoulos EN. The relation between bone marrow angiogenesis and the proliferation index Ki-67 in multiple myeloma. J Clin Pathol 2004; 57: 856-860. (Pubitemid 39061436)
7. Yaccoby S. Advances in the understanding of myeloma bone disease and tumour growth. Br J Haematol 2010; 149: 311-321.
8. Roodman GD. Targeting the bone microenvironment in multiple myeloma. J Bone Miner Metab 2010; 28: 244-250.
9. Dankbar B, Padro T, Leo R, Feldmann B, Kropff M, Mesters RM et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636. (Pubitemid 30210543)
10. Podar K, Anderson KC. The pathophisiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005; 105: 1383-1395. (Pubitemid 40223651)
11. Bisping G, Leo R, Wenning D, Dankbar B, Padró T, Kropff M et al. Paracrine interactions of basic fibroblast growth factor and interleukin-6 in multiple myeloma. Blood 2003; 101: 2775-2783. (Pubitemid 36857643)
12. Colla S, Morandi F, Lazzaretti M, Polistena P, Svaldi M, Coser P et al. Do human myeloma cells directly produce basic FGF? Blood 2003; 102: 3071-3072.
13. Shapiro VS, Mollenauer MN, Weiss A. Endogenous CD28 expressed on myeloma cells up-regulates interleukin-8 production: implications for multiple myeloma progression. Blood 2001; 98: 187-193.
14. Giuliani N, Colla S, Lazzaretti M, Sala R, Roti G, Mancini C et al. Pro-angiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood 2003; 102: 638-645. (Pubitemid 36841986)
15. Colla S, Morandi F, Lazzaretti M, Rizzato R, Lunghi P, Bonomini S et al. Human myeloma cells express the bone regulating gene Runx2/Cbfa1 and produce osteopontin that is involved in angiogenesis in multiple myeloma patients. Leukemia 2005; 19: 2166-2176. (Pubitemid 41741611)
16. Brahimi-Horn MC, Chiche J, Pouysségur J. Hypoxia and cancer. J Mol Med 2007; 85: 1301-1307. (Pubitemid 50004093)
17. Rankin EB, Giaccia AJ. The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 2008; 15: 678-685. (Pubitemid 351405072)
18. Liao D, Johnson RS. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007; 26: 281-290. (Pubitemid 47101669)
19. Weidemann A, Johnson RS. Biology of HIF-1a. Cell Death Differ 2008; 15: 621-627.
20. Lisy K, Peet DJ. Turn me on: regulating HIF transcriptional activity. Cell Death Differ 2008; 15: 642-649. (Pubitemid 351405067)
21. Yee Koh M, Spivak-Kroizman TR, Powis G. HIF-1 regulation: not so easy come, easy go. Trends Biochem Sci 2008; 33: 526-634.
22. Semenza GL. Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol 2009; 19: 12-16.
23. Hirota K, Semenza GL. ReguIation of angiogenesis by hypoxia-inducibIe factor 1. Crit Rev OncoI Hematol 2006; 59: 15-26.
24. Utting JC, Flanagan AM, Brandao-Burch A, Orriss IR, Arnett TR. Hypoxia stimulates osteoclast formation from human peripheral blood. Cell Biochem Funct 2010; 28: 374-380.
25. Bozec A, Bakiri L, Hoebertz A, Eferl R, Schilling AF, Komnenovic V et al. Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia. Nature 2008; 454: 221-225. (Pubitemid 351969891)
26. Hiraga T, Kizaka-Kondoh S, Hirota K, Hiraoka M, Yoneda T. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res 2007; 67: 4157-4163. (Pubitemid 46815061)
27. Colla S, Storti P, Donofrio G, Todoerti K, Bolzoni M, Lazzaretti M et al. Low bone marrow oxygen tension and hypoxia-inducible factor-1a overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. Leukemia 2010; 24: 1967-1970.
28. Zhang J, Sattler M, Tonon G, Grabher C, Lababidi S, Zimmerhackl A et al. Targeting angiogenesis via a c-Myc/hypoxia-inducible factor-1alpha-dependent pathway in multiple myeloma. Cancer Res 2009; 69: 5082-5090.
29. Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25: 1533-1542.
30. Azab AK, Hu J, Quang P, Azab F, Pitsillides C, Awwad R et al. Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features. Blood 2012; 119: 5782-5794.
31. Hu J, Handisides DR, Van Valckenborgh E, De Raeve H, Menu E, Vande Broek I et al. Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug. Blood 2010; 116: 1524-1527.
32. Storti P, Donofrio G, Colla S, Airoldi I, Bolzoni M, Agnelli L et al. HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. Leukemia 2011; 25: 527-537.
33. Campbell RA, Berenson JR. Animal models of multiple myeloma and their utility in drug discovery. Curr Protoc Pharmacol 2008, Chapter 14, Unit 14: 9.
34. D'Souza S, del Prete D, Jin S, Sun Q, Huston AJ, Kostov FE et al. Gfi1 expressed in bone marrow stromal cells is a novel osteoblast suppressor in patients with multiple myeloma bone disease. Blood 2011; 118: 6871-6880.
35. Asosingh K, De Raeve H, de Ridder M, Storme GA, Willems A, Van Riet I et al. Role of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression. Haematologica 2005; 90: 810-817. (Pubitemid 40897223)
36. Hu Y, Kirito K, Yoshida K, Mitsumori T, Nakajima K, Nozaki Y et al. Inhibition of hypoxia-inducible factor-1 function enhances the sensitivity of multiple myeloma cells to melphalan. Mol Cancer Ther 2009; 8: 2329-2338.
37. Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O et al. The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells. Blood 2007; 109: 4470-4477. (Pubitemid 46743417)
38. Veschini L, Belloni D, Foglieni C, Cangi MG, Ferrarini M, Caligaris-Cappio F et al. Hypoxia-inducible transcription factor-1 alpha determines sensitivity of endothelial cells to the proteosome inhibitor bortezomib. Blood 2007; 109: 2565-2570. (Pubitemid 46425903)
39. Colla S, Tagliaferri S, Morandi F, Lunghi P, Donofrio G, Martorana D et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood 2007; 110: 4464-4475. (Pubitemid 351377813)
40. Negaard HF, Iversen N, Bowitz-Lothe IM, Sandset PM, Steinsvik B, Ostenstad B et al. Increased bone marrow microvascular density in haematological malignancies is associated with differential regulation of angiogenic factors. Leukemia 2009; 23: 162-169.
41. Arendt BK, Velazquez-Dones A, Tschumper RC, Howell KG, Ansell SM, Witzig TE et al. Interleukin 6 induces monocyte chemoattractant protein-1 expression in myeloma cells. Leukemia 2002; 16: 2142-2147. (Pubitemid 35203460)
42. Van Valckenborgh E, Bakkus M, Munaut C, Noël St A, Pierre Y, Asosingh K et al. Upregulation of matrix metalloproteinase-9 in murine 5T33 multiple myeloma cells by interaction with bone marrow endothelial cells. Int J Cancer 2002; 101: 512-518.
43. Purushothaman A, Chen L, Yang Y, Sanderson RD. Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma. J Biol Chem 2008; 283: 32628-32636.
44. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-675. (Pubitemid 30463390)
45. Giuliani N, Colla S, Sala R, Moroni M, Lazzaretti M, La Monica S et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 2002; 100: 4615-4621. (Pubitemid 35429706)
46. Hatfield KJ, Bedringsaas SL, Ryningen A, Gjertsen BT, Bruserud O. Hypoxia increases HIF-1a expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw 2010; 21: 154-164.
47. Nishida C, Kusubata K, Tashiro Y, Gritli I, Sato A, Ohki-Koizumi M et al. MT1-MMP plays a critical role in hematopoiesis by regulating HIF-mediated chemokine/cytokine gene transcription within niche cells. Blood 2012; 119: 5405-5416.
48. Krishnamachary B, Berg-Dixon S, Kelly B, Agani F, Feldser D, Ferreira G et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. Cancer Res 2003; 63: 1138-1143. (Pubitemid 36278449)
49. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW et al. Evaluating hypoxia-inducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258. (Pubitemid 41161256)
50. Greenberger LM, Horak ID, Filpula D, Sapra P, Westergaard M, Frydenlund HF et al. A RNA antagonist of hypoxia-inducible factor-1alpha, EZN-2968, inhibits tumor cell growth. Mol Cancer Ther 2008; 7: 3598-3608.